Actavis (ACT) PT Lifted to $340 at Argus

Actavis (ACT) PT Lifted to $352 at Canaccord Genuity

Canaccord Genuity reiterated a Buy rating and boosted its price target on Actavis (NYSE: ACT) to $352.00 (from $300.00)

For an analyst ratings summary and ratings history on Actavis click here. For more ratings news on Actavis click here.

Shares of Actavis closed at $284.00 yesterday.

Actavis (ACT) PT Lifted to $345 at Guggenheim Following Q4 Results and Update

Guggenheim analyst Louise Chen reiterated a Buy rating and raised her price target on Actavis (NYSE: ACT) to $345.00 (from $300.00) following Q4 results and outlook.

Chen comments, "We are raising our PT to $345 from $300 post a 4Q14 beat and strong outlook for '15. We use a... More

Actavis (ACT) to Adopt 'Allergan' Name

Actavis plc (NYSE: ACT) today announced that it will adopt a new corporate name Allergan following the anticipated successful completion of the acquisition of Allergan, Inc (NYSE: AGN). The Company said that it intends to use the Allergan name as its corporate name and for its global branded pharmaceutical portfolio, and will retain the Actavis name for select geographic regions and product portfolios. The change in corporate name would be subject to approval by Actavis' shareholders at its Annual General Meeting later this year.

"The pending... More

Actavis (ACT) Updates on Key Pipeline Program, Potential Market Opportunities

Actavis (NYSE: ACT) provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

"Today, we provided an overview of the rationalized, standalone pharmaceutical development pipeline that will power Actavis' ascent into the fastest growing and most dynamic growth pharmaceutical company... More

Actavis (ACT) Reports In-Line Q4 EPS; Guides FY15 EPS, Revs

Actavis (NYSE: ACT) reported Q4 EPS of $3.91, in-line with the analyst estimate of $3.91. Revenue for the quarter came in at $4.01 billion versus the consensus estimate of $3.84 billion.

Actavis sees FY2015 EPS of $16.30-$17.30, versus the consensus of $16.63. Actavis sees FY2015 revenue of $15.0 billion,... More